<DOC>
	<DOCNO>NCT00920517</DOCNO>
	<brief_summary>Dengue fever , cause dengue virus , major health problem tropical subtropical region world . The purpose study test safety immune response new dengue virus vaccine healthy adult .</brief_summary>
	<brief_title>Safety Immune Response Two Doses rDEN2/4delta30 Dengue Vaccine</brief_title>
	<detailed_description>Dengue virus , cause dengue fever dengue shock syndrome , major cause morbidity mortality several world 's tropical subtropical region . The rDEN2/4delta30 ( ME ) vaccine live attenuate dengue virus vaccine may protective dengue virus serotype 2 ( DEN2 ) . The purpose study evaluate safety immunogenicity rDEN2/4delta30 ( ME ) vaccine healthy adult . This study last approximately 5 7 month 25 study visit . Participants randomly assign one two cohort . Participants Cohort 1 receive injection rDEN2/4delta30 ( ME ) placebo vaccine Days 0 180 . Participants Cohort 2 receive injection rDEN2/4delta30 ( ME ) placebo vaccine Days 0 120 . Participants ask record temperature diary 16 day vaccination . At study visit physical examination , symptom history , blood urine collection occur .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Good general health determine mean screen procedure . Available duration study ( 32 week cohort 1 23 week cohort 2 ) Willing use effective method contraception Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history , physical examination , and/or laboratory study Behavioral , cognitive , psychiatric disease opinion investigator affect ability volunteer understand cooperate requirement study protocol Neutropenia define ANC â‰¤1500/mm3 ALT level laboratorydefined upper limit normal Serum creatinine level laboratorydefined upper limit normal Any condition , opinion investigator , would jeopardize safety right volunteer participate trial would render subject unable comply protocol . Medical , occupational , family problem result alcohol illicit drug use past 12 month History severe allergic reaction anaphylaxis Severe asthma ( emergency room visit hospitalization within last 6 month ) Positive HIV1 serology screen confirmatory assay Positive hepatitis C virus ( HCV ) screen confirmatory assay Positive hepatitis B surface antigen ( HBsAg ) enzymelinked immunosorbent assay ( ELISA ) Known immunodeficiency syndrome Use corticosteroid ( exclude topical nasal ) immunosuppressive drug within 30 day start study Receipt live vaccine within 4 week kill vaccine within 2 week prior entry study Has spleen surgically remove Receipt blood product within 6 month prior study entry History serologic evidence previous dengue virus infection flavivirus infection ( e.g . yellow fever virus , St. Louis encephalitis , West Nile virus ) . Previous receipt yellow fever dengue vaccine ( licensed experimental ) Persons receive investigational agent 30 day prior study entry Persons definite plan travel dengue endemic area study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>